76 completed, 3 recruiting, 1 active not recruiting, 1 terminated. 82 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 82 | Completed 76, Recruiting 3, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 3 | Completed 2, Recruiting 1 |
Follow Rabeprazole: new trials by email Literature Review of Rabeprazole trials Research Report on Rabeprazole
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21) DZD8586, Rabeprazole - Healthy | Phase 1 | Recruiting | Dizal Pharmaceuticals | 26 | 2026-10-23 | 2026-11-06 |
| A Study of RO7890597 in Healthy Adult Volunteers RO7890597, Placebo, Rabeprazole - Healthy Volunteers | Phase 1 | Recruiting | Genentech, Inc. | 139 | 2026-08-28 | 2026-11-17 |
| A Study on the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of HMPL-760 Capsules HMPL-760, Rabeprazole and HMPL-760 - Healthy Participants | Phase 1 | Completed | Hutchmed | 24 | 2026-06-30 | 2026-09-18 |
| A Study to Learn How Different Forms of the Study Medicine Called PF-08049820 Are Absorbed and Eliminated in Healthy Adults PF-08049820, Rabeprazole - Healthy Adults, Healthy | Phase 1 | Completed | Pfizer | 24 | 2026-05-13 | 2026-10-01 |
| A Study to Evaluate the Effect of Food and Proton Pump Inhibitor on the Pharmacokinetics of ZN-A-1041 in Healthy Participants ZN-A-1041 Formulation 1, ZN-A-1041 Formulation 2, Rabeprazole - Healthy Volunteers | Phase 1 | Completed | Genentech, Inc. | 24 | 2025-11-21 | 2026-05-11 |
| A Study to Learn if a Medicine That Reduces Stomach Acid Affects the Blood Level of Study Medicine PF-08049820 in Healthy Chinese Adults. PF-08049820, Rabeprazole - Healthy Adults | Phase 1 | Completed | Pfizer | 18 | 2025-11-03 | 2026-09-09 |
| A Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN110755 VRN110755, Rabeprazole - Healthy | Phase 1 | Completed | Voronoi, Inc | 25 | 2025-08-27 | 2026-05-08 |
| Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole - Healthy | Phase 1 | Completed | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | 24 | 2025-08-21 | 2026-05-08 |
| Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid LY4100511, Rabeprazole - Healthy Participants | Phase 1 | Terminated | Eli Lilly and Company | 1 | 2025-04-08 | 2026-09-09 |
| Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib Saruparib, Digoxin, Furosemide - Advanced Solid Malignancies | Phase 1 | Active not recruiting | AstraZeneca | 41 | 2025-03-25 | 2026-10-01 |
| A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) DCC-3009, Rabeprazole - Gastrointestinal Stromal Tumor (GIST) | Phase 1 / Phase 2 | Recruiting | Deciphera Pharmaceuticals, LLC | 155 | 2024-12-10 | 2026-11-12 |
| Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants BMS-986365, Rabeprazole - Healthy Participants | Phase 1 | Completed | Celgene | 102 | 2024-05-28 | 2025-03-06 |
| Clinical Study Aiming to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Administration of ZE50-0134 at 5 Dose Levels in Healthy Volunteers ZE50-0134 or placebo, Rabeprazole 20 mg, Itraconazole (200 mg) - Healthy | Phase 1 | Completed | Lomond Therapeutics Holdings, Inc. | 104 | 2024-05-21 | 2025-12-05 |
| A Study to Assess the Potential for Gastric-pH Dependent Drug-Drug Interactions of BIIB122 With a Proton Pump Inhibitor in Healthy Participants BIIB122, Rabeprazole - Healthy Volunteer | Phase 1 | Completed | Biogen | 18 | 2024-02-12 | 2024-07-19 |
| A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014) Embibatinib, Rabeprazole, Midazolam - Healthy | Phase 1 | Completed | Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 196 | 2023-12-21 | 2026-10-22 |
| A Study to Learn How a Medicine That Reduces Stomach Acid Affects the Level of Sisunatovir in the Blood of Healthy Adults. Sisunatovir, Rabeprazole 40 mg, Sisunatovir suspension - Healthy | Phase 1 | Completed | Pfizer | 40 | 2023-11-03 | 2025-04-24 |
| A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics of PC14586 in Healthy Participants PC14586, Rabeprazole, Famotidine - Healthy Volunteers | Phase 1 | Completed | PMV Pharmaceuticals, Inc | 28 | 2023-09-19 | 2024-11-13 |
| Study of Single and Multiple Ascending Doses of ZE46-0134 in Healthy Volunteers ZE46-0134 or placebo, Rabeprazole, 20mg oral, Itraconazole (200 mg) - AML | Phase 1 | Completed | Lomond Therapeutics Holdings, Inc. | 112 | 2023-07-28 | 2025-12-09 |
| A Study of Maribavir Pediatric Formulation in Healthy Adult Participants Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole - Healthy Volunteers | Phase 1 | Completed | Takeda | 32 | 2023-07-25 | 2024-09-26 |
| Evaluation of the Effect of Rifampin and Rabeprazole on the Pharmacokinetics of Camlipixant Camlipixant, Rabeprazole, Rifampin - Cough, Healthy | Phase 1 | Completed | Bellus Health Inc. - a GSK company | 42 | 2023-06-21 | 2024-12-04 |
Showing 20 of 82. Sign in to see all of them.
Gastroesophageal Reflux (8) · Amyotrophic Lateral Sclerosis (2) · Lymphoma (2) · Neoplasms (2) · Recurrence (2) · Autoimmune Diseases (1) · COVID-19 (1) · Cholangiocarcinoma (1) · Colorectal Neoplasms (1) · Communicable Diseases (1) · Cough (1) · Dermatitis, Atopic (1) · Gastrointestinal Stromal Tumors (1) · Hematologic Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Genentech, Inc. (10) · Pfizer (10) · AstraZeneca (5) · Hutchmed (4) · Eisai Co., Ltd. (3) · Janssen Research & Development, LLC (3) · Addpharma Inc. (2) · Biogen (2) · Bristol-Myers Squibb (2) · Celgene (2) · Haihe Biopharma Co., Ltd. (2) · Hutchison Medipharma Limited (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · Lomond Therapeutics Holdings, Inc. (2) · Mylan Pharmaceuticals Inc (2)
United States (40) · United Kingdom (10) · China (8) · Australia (4) · Canada (4) · Germany (4) · South Korea (4) · Belgium (3) · France (2) · India (2) · Japan (2) · Netherlands (2) · Poland (2) · Brazil (1) · Bulgaria (1)
James D Carlson, Pharm. D. (2) · Kai Shibata (2) · Scott Holden, M.D. (2) · Seunghwan Lee, M.D.,Ph.D (2) · Youngiun Kim, MD (2) · Ahmed Elshafeey, Ph.D. Pharma (1)
PMID 17116123, PMID 23689261, PMID 23980906, PMID 27129014, PMID 27154174, PMID 30536154, PMID 35445718, PMID 37705327, PMID 38359854, PMID 39087871, PMID 39711068, PMID 40077903, PMID 41058119
2017 (4), 2015 (2), 2008 (1), 2018 (1), 2019 (1), 2023 (1)